A Phase 4 interventional study of ganagliflozin and Placebo in T2DM (Type 2 Diabetes Mellitus) and CKD - Chronic Kidney Disease, sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (part of Huadong Medicine Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd. — 7 open to participants now, 7 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Huadong Medicine Co., Ltd..
Among the 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd., this one has the largest planned enrollment, is one of 5 that started in 2025, is one of 2 in phase 4, and was the 5th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,244 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 395 across the 10 interventional studies. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., one of the names counted as Huadong Medicine Co., Ltd.. Under that name alone:
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. is the lead sponsor of 50 studies on the registry; 38 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd. that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07082114Phase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | 2027-02-16 |
| NCT07394114Phase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | 2027-08-28 |
| NCT07417306Phase 3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | 2027-08-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Diabetes Mellitus, Type 2 by Huadong Medicine Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. The efficacy and safety will be evaluated by comparing the effects of Ganagliflozin tablets and placebo tablets added to the current background treatment over 120 weeks
A phase IV clinical study on the efficacy and safety of Ganagliflozin in treating patients with type 2 diabetes and chronic kidney disease (multicenter, randomized, double-blind, placebo parallel controlled). 1244 subjects all received a stable dose of ACEi or ARB for at least 4 weeks before enrollment.
Efficacy assessment: Compared with the placebo group, time to the first occurrence of kidney disease progression and the changes in eGFR slope, UACR, and score of KDQOL-36 were evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 mg Once daily, 120 weeks
Drug: ganagliflozin
50 mg Once daily, 120 weeks
Drug: Placebo
50 mg Once daily, 120 weeks
50 mg Once daily, 120 weeks
The average change in eGFR as measured by the total slope of eGFR from baseline to week 120
Time frame: Baseline to Week 120
Time to the first occurrence of kidney disease progression
The progression of kidney disease is defined as: 1. maintenance dialysis or 2. receipt of a kidney transplant or 3. sustained decline in eGFR to \< 15 mL/min/1.73m\^2 or 4. a sustained decline of ≥ 40% in eGFR from baseline or 5. doubling of serum creatinine or 6. renal death
Time frame: from baseline to Week 120
The proportion of subjects with a total slope of eGFR greater than -3 mL/min/1.73 m²/year from baseline to week 120
Time frame: from baseline to week 120
The average change in eGFR as measured by the total slope of eGFR from baseline to week 2 and week 8,from week 2 and week 8 to week 120
Time frame: from baseline to week 2 and week 8,from week 2 and week 8 to week 120
The changes in urine albumin-to-creatinine ratio (UACR) at each visit compared to the baseline
Time frame: from baseline to week 120
Changes in the scores of the Kidney Disease Quality of Life-36 Scale (KDQOL-36) compared to the baseline
The higher the score, the better the patient's quality of life related to CKD
Time frame: from baseline to week 120
Changes in the scores of the European Five-Dimensional Health Scale (EQ-5D-5L) compared to the baseline
Higher the score means the better quality of life
Time frame: from baseline to week 120
time to the first occurrence of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure
Time frame: from baseline to week 120
Changes in liver stiffness measurement (LSM) of liver transient elastography
Time frame: from baseline to week 52 and 120
change in the staging of diabetic retinopathy measured by non-mydriatic fundus photography
Time frame: from baseline to week 52 and 120
Changes in control attenuation index (Cap) of liver transient elastography
Time frame: from baseline to week 52 and 120
Start is estimated for Nov 2025; primary completion for Oct 2031, 71 months later.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 71 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Janagliflozin
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. →